Sleep Apnea, Metabolic Disease, and the Cutting Edge of Therapy

Obstructive sleep apnea (OSA) is common, and many cross-sectional and longitudinal studies have established OSA as an independent risk factor for the development of a variety of adverse metabolic disease states, including hypertension, insulin resistance, type 2 diabetes, nonalcoholic fatty liver disease, dyslipidemia, and atherosclerosis. Nasal continuous positive airway pressure (CPAP) has long been the mainstay of therapy for OSA, but definitive studies demonstrating the efficacy of CPAP in improving metabolic outcomes, or in reducing incident disease burden, are lacking; moreover, CPAP has variable rates of adherence.

Source: Metabolism - Clinical and Experimental - September 28, 2017 Category: Biomedical Science Authors: Matthew Light, Karen McCowen, Atul Malhotra, Omar A. Mesarwi Source Type: research